CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CDC5L (ImmuneEditome ID:988)

1. Gene summary of enriched editing regions for CDC5L

check button Gene summary
Gene informationGene symbol

CDC5L

Gene ID

988

GeneSynonymsCDC5|CDC5-LIKE|CEF1|PCDC5RP|dJ319D22.1
GeneCytomap

6p21.1

GeneTypeprotein-coding
GeneDescriptioncell division cycle 5-like protein|CDC5 cell division cycle 5-like|Cdc5-related protein|dJ319D22.1 (CDC5-like protein)|pombe cdc5-related protein
GeneModificationdate20230329
UniprotIDQ99459
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr6:44449351-44450152:+ENST00000371477.3ENSG00000096401.7CDC5LUTR3FLAM_C,AluSx,L1M5chr6:44449351-44450152:+.alignment


Top

2. Tumor-specific enriched editing regions for CDC5L


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr6:44449351-44450152:+BRCAEER4.0311e-07image
ENSG00000096401.7,CDC5LBRCAEAG4.1701e-07image
chr6:44449351-44450152:+LUSCEER1.8264e-02image
ENSG00000096401.7,CDC5LLUSCEAG1.8264e-02image
ENSG00000096401.7,CDC5LPRADEAG3.2546e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr6:44449351-44450152:+ESCAPathEER2.1527e-022.6823e-02-0.1973image
ENSG00000096401.7,CDC5LESCAPathEAG1.6053e-022.4091e-02-0.2009image
ENSG00000096401.7,CDC5LREADPathEAG1.3365e-021.5971e-02-0.3613image
ENSG00000096401.7,CDC5LTHCAPathEAG2.9183e-024.0483e-030.1537image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for CDC5L


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr6:44449351-44450152:+ESCAEERENSG00000105355,PLIN30.29092.8985e-023.1768e-070.4107imageNNNANK_cells_restingGSVA_HALLMARK_P53_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for CDC5L


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000096401.7,CDC5L
ESCAEAGIRENSG00000158828.5chr120648504:20648632:20649020:20649231-0.15761.7882e-026.3330e-08-0.4350imageNADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RNF219;RTCB;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZC3H7B;ZNF184PINK1NK_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000096401.7,CDC5L
ESCAEAGESENSG00000125629.10chr2118088473:118088541:118096418:118096800:118103196:118103281-0.34561.9136e-026.5337e-08-0.4332imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NANK_cells_restingGSVA_HALLMARK_HYPOXIA
chr6:44449351-44450152:+
ESCAEERIRENSG00000158828.5chr120648504:20648632:20649020:20649231-0.15791.4548e-025.7195e-08-0.4363imageNNPINK1NK_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr6:44449351-44450152:+
ESCAEERESENSG00000125629.10chr2118088473:118088541:118096418:118096800:118103196:118103281-0.35221.2484e-024.1582e-08-0.4389imageNNNANK_cells_restingGSVA_HALLMARK_HYPOXIA
ENSG00000096401.7,CDC5L
TGCTEAGMEXENSG00000243716.6chr1622491706:22491826:22513423:22513521:22513521:22513610:22513763:225138340.34622.3647e-032.2034e-060.4267imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;LSM11;MBNL2;MSI1;MSI2;NOP56;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
ENSG00000096401.7,CDC5L
TGCTEAGIRENSG00000183889.8chr1616327735:16328198:16328650:163288070.37562.5668e-032.0542e-060.4040imageNADAR;BUD13;ELAVL1;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;MBNL2;NUMA1;SRSF1;SRSF10;SRSF3;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF2;YTHDF1NAMacrophages_M2GSVA_HALLMARK_ALLOGRAFT_REJECTION
ENSG00000096401.7,CDC5L
TGCTEAGA5ENSG00000204463.8chr631651655:31651776:31652512:31652648:31652399:316526480.37471.4169e-033.9836e-060.4008imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184BAG6B_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000096401.7,CDC5L
TGCTEAGIRENSG00000179820.11chr1953869405:53869598:53869753:53869838-0.29597.7899e-031.6094e-05-0.4129imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184MYADMMacrophages_M2GSVA_HALLMARK_COAGULATION
ENSG00000096401.7,CDC5L
TGCTEAGESENSG00000132005.4chr1913977991:13978086:13978749:13979079:13979446:139795420.27851.4337e-034.8603e-090.5286imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZFP36;ZNF184RFX1B_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
ENSG00000096401.7,CDC5L
TGCTEAGIRENSG00000166140.13chr1540809827:40809970:40810153:40810216-0.30507.8094e-031.4354e-06-0.4052imageNACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NANeutrophilsGSVA_HALLMARK_TGF_BETA_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for CDC5L


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000096401.7,CDC5LACCEAGMonocytes2.6637e-03-0.5965image
chr6:44449351-44450152:+BLCAEERMacrophages_M12.9365e-040.2392image
ENSG00000096401.7,CDC5LBLCAEAGMacrophages_M17.6051e-040.2224image
chr6:44449351-44450152:+BRCAEERT_cells_regulatory_(Tregs)4.3953e-050.1343image
ENSG00000096401.7,CDC5LBRCAEAGT_cells_regulatory_(Tregs)3.7260e-050.1354image
chr6:44449351-44450152:+CESCEERT_cells_CD4_memory_resting1.7124e-02-0.1621image
ENSG00000096401.7,CDC5LCESCEAGT_cells_CD4_memory_resting1.7124e-02-0.1621image
ENSG00000096401.7,CDC5LCHOLEAGPlasma_cells3.2378e-02-0.4573image
ENSG00000096401.7,CDC5LCOADEAGEosinophils4.0077e-050.3600image
chr6:44449351-44450152:+ESCAEERNK_cells_resting3.2674e-030.2435image
ENSG00000096401.7,CDC5LESCAEAGMast_cells_activated2.7150e-030.2481image
ENSG00000096401.7,CDC5LGBMEAGT_cells_CD4_naive5.7718e-030.2827image
ENSG00000096401.7,CDC5LHNSCEAGMacrophages_M11.8650e-030.1804image
chr6:44449351-44450152:+KIRCEERT_cells_CD81.1398e-020.1479image
ENSG00000096401.7,CDC5LKIRCEAGT_cells_CD81.1398e-020.1479image
ENSG00000096401.7,CDC5LKIRPEAGT_cells_CD4_memory_activated1.9683e-040.3658image
ENSG00000096401.7,CDC5LLGGEAGMonocytes1.4183e-020.1615image
chr6:44449351-44450152:+LIHCEERT_cells_gamma_delta1.8720e-020.1354image
ENSG00000096401.7,CDC5LLIHCEAGT_cells_gamma_delta1.8720e-020.1354image
chr6:44449351-44450152:+LUADEERT_cells_CD4_memory_activated8.4794e-040.1874image
ENSG00000096401.7,CDC5LLUADEAGT_cells_CD4_memory_activated8.4794e-040.1874image
chr6:44449351-44450152:+LUSCEERNeutrophils6.9205e-030.1546image
ENSG00000096401.7,CDC5LLUSCEAGNeutrophils6.9205e-030.1546image
chr6:44449351-44450152:+OVEERT_cells_CD81.2220e-020.1815image
ENSG00000096401.7,CDC5LOVEAGT_cells_CD81.2087e-020.1818image
ENSG00000096401.7,CDC5LPAADEAGNeutrophils3.1960e-02-0.2513image
ENSG00000096401.7,CDC5LPCPGEAGMast_cells_resting2.8255e-02-0.1889image
ENSG00000096401.7,CDC5LPRADEAGDendritic_cells_resting9.7451e-05-0.2332image
ENSG00000096401.7,CDC5LREADEAGT_cells_CD82.9200e-020.3253image
chr6:44449351-44450152:+SARCEERMacrophages_M12.0300e-030.2364image
ENSG00000096401.7,CDC5LSARCEAGMacrophages_M12.0300e-030.2364image
chr6:44449351-44450152:+SKCMEERT_cells_CD82.0186e-040.2330image
ENSG00000096401.7,CDC5LSKCMEAGT_cells_CD82.0186e-040.2330image
chr6:44449351-44450152:+STADEERT_cells_CD4_memory_activated3.6313e-040.2242image
ENSG00000096401.7,CDC5LSTADEAGT_cells_CD4_memory_activated3.6970e-040.2239image
ENSG00000096401.7,CDC5LTGCTEAGMacrophages_M21.0527e-04-0.3276image
ENSG00000096401.7,CDC5LTHCAEAGT_cells_CD4_memory_activated3.7815e-040.1887image
ENSG00000096401.7,CDC5LTHYMEAGT_cells_CD4_naive1.8347e-03-0.4616image
ENSG00000096401.7,CDC5LUCECEAGDendritic_cells_activated1.6226e-020.2288image
ENSG00000096401.7,CDC5LUCSEAGDendritic_cells_resting2.7451e-02-0.3675image


Top

6. Enriched editing regions and immune gene sets for CDC5L


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000096401.7,CDC5LHNSCEAG2.8830e-020.12738.7656e-04-0.19275.4559e-030.16144.3989e-030.1654image
chr6:44449351-44450152:+LUADEER2.2843e-030.17161.6153e-020.13579.6678e-030.14582.3999e-050.2359image
ENSG00000096401.7,CDC5LLUADEAG2.2843e-030.17161.6153e-020.13579.6678e-030.14582.3999e-050.2359image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr6:44449351-44450152:+BLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.0017e-090.3864image
ENSG00000096401.7,CDC5LBLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.5920e-080.3538image
chr6:44449351-44450152:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0550e-190.2887image
ENSG00000096401.7,CDC5LBRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.1750e-190.2871image
chr6:44449351-44450152:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.7483e-040.2527image
ENSG00000096401.7,CDC5LCESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.7483e-040.2527image
ENSG00000096401.7,CDC5LCHOLGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.4232e-02-0.5148image
ENSG00000096401.7,CDC5LCOADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG2.4437e-020.2020image
ENSG00000096401.7,CDC5LESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.5893e-040.2934image
chr6:44449351-44450152:+ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.7401e-040.2925image
ENSG00000096401.7,CDC5LGBMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.3888e-02-0.2530image
ENSG00000096401.7,CDC5LHNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1815e-090.3394image
chr6:44449351-44450152:+KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.4309e-05-0.2509image
ENSG00000096401.7,CDC5LKIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.4309e-05-0.2509image
ENSG00000096401.7,CDC5LKIRPGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG2.7815e-03-0.2975image
ENSG00000096401.7,CDC5LLGGGSVA_HALLMARK_MYC_TARGETS_V2EAG5.7108e-09-0.3722image
chr6:44449351-44450152:+LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER9.8008e-040.1891image
ENSG00000096401.7,CDC5LLIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG9.8008e-040.1891image
ENSG00000096401.7,CDC5LLUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.2500e-060.2592image
chr6:44449351-44450152:+LUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.2500e-060.2592image
ENSG00000096401.7,CDC5LLUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.6205e-070.2868image
chr6:44449351-44450152:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.6205e-070.2868image
ENSG00000096401.7,CDC5LMESOGSVA_HALLMARK_HYPOXIAEAG1.4479e-020.3509image
ENSG00000096401.7,CDC5LOVGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.9932e-04-0.2502image
chr6:44449351-44450152:+OVGSVA_HALLMARK_MITOTIC_SPINDLEEER4.6016e-04-0.2517image
ENSG00000096401.7,CDC5LPAADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.1360e-02-0.2947image
ENSG00000096401.7,CDC5LPCPGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.4201e-02-0.2106image
ENSG00000096401.7,CDC5LPRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.8644e-03-0.1871image
ENSG00000096401.7,CDC5LREADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1049e-020.3754image
chr6:44449351-44450152:+SARCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER4.4417e-050.3096image
ENSG00000096401.7,CDC5LSARCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG4.4417e-050.3096image
chr6:44449351-44450152:+SKCMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.0278e-050.2750image
ENSG00000096401.7,CDC5LSKCMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.0278e-050.2750image
chr6:44449351-44450152:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.5921e-060.2888image
ENSG00000096401.7,CDC5LSTADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.7035e-060.2884image
ENSG00000096401.7,CDC5LTGCTGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.0239e-04-0.3281image
ENSG00000096401.7,CDC5LTHCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG8.8481e-05-0.2077image
ENSG00000096401.7,CDC5LTHYMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.1567e-040.5235image
ENSG00000096401.7,CDC5LUCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.8629e-020.2240image
ENSG00000096401.7,CDC5LUCSGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.5678e-02-0.3715image


Top

7. Enriched editing regions and drugs for CDC5L


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000096401.7,CDC5LACCABT.263EAG5.2527e-030.5620image
chr6:44449351-44450152:+BLCAEHT.1864EER2.7176e-070.3347image
ENSG00000096401.7,CDC5LBLCAEHT.1864EAG1.1652e-060.3168image
ENSG00000096401.7,CDC5LBRCAABT.263EAG4.8491e-060.1502image
chr6:44449351-44450152:+BRCAABT.263EER5.6467e-060.1493image
chr6:44449351-44450152:+CESCCI.1040EER1.1450e-04-0.2595image
ENSG00000096401.7,CDC5LCESCCI.1040EAG1.1450e-04-0.2595image
ENSG00000096401.7,CDC5LCHOLBMS.536924EAG9.4745e-040.6546image
ENSG00000096401.7,CDC5LCOADGefitinibEAG2.3437e-03-0.2709image
ENSG00000096401.7,CDC5LESCAGefitinibEAG1.0786e-05-0.3588image
chr6:44449351-44450152:+ESCAGefitinibEER8.3833e-06-0.3630image
ENSG00000096401.7,CDC5LGBMAZD8055EAG3.9136e-040.3583image
ENSG00000096401.7,CDC5LHNSCKU.55933EAG8.2946e-09-0.3276image
chr6:44449351-44450152:+KIRCABT.888EER3.3139e-04-0.2090image
ENSG00000096401.7,CDC5LKIRCABT.888EAG3.3139e-04-0.2090image
ENSG00000096401.7,CDC5LKIRPAZD.0530EAG1.5684e-030.3137image
ENSG00000096401.7,CDC5LLGGCytarabineEAG2.7943e-080.3561image
chr6:44449351-44450152:+LIHCAICAREER1.2859e-05-0.2485image
ENSG00000096401.7,CDC5LLIHCAICAREAG1.2859e-05-0.2485image
ENSG00000096401.7,CDC5LLUADKU.55933EAG2.5676e-06-0.2618image
chr6:44449351-44450152:+LUADKU.55933EER2.5676e-06-0.2618image
ENSG00000096401.7,CDC5LLUSCAZD6244EAG5.7403e-05-0.2286image
chr6:44449351-44450152:+LUSCAZD6244EER5.7403e-05-0.2286image
ENSG00000096401.7,CDC5LMESODMOGEAG2.5948e-03-0.4251image
ENSG00000096401.7,CDC5LOVAZ628EAG6.6263e-05-0.2853image
chr6:44449351-44450152:+OVAZ628EER6.0997e-05-0.2866image
ENSG00000096401.7,CDC5LPAADFTI.277EAG2.7687e-03-0.3453image
ENSG00000096401.7,CDC5LPRADBicalutamideEAG6.3624e-040.2051image
ENSG00000096401.7,CDC5LREADLapatinibEAG9.2157e-030.3840image
chr6:44449351-44450152:+SARCAG.014699EER1.0701e-070.3961image
ENSG00000096401.7,CDC5LSARCAG.014699EAG1.0701e-070.3961image
chr6:44449351-44450152:+SKCMAG.014699EER2.6873e-060.2924image
ENSG00000096401.7,CDC5LSKCMAG.014699EAG2.6873e-060.2924image
chr6:44449351-44450152:+STADCisplatinEER8.4356e-08-0.3315image
ENSG00000096401.7,CDC5LSTADCisplatinEAG8.3255e-08-0.3317image
ENSG00000096401.7,CDC5LTGCTErlotinibEAG3.9605e-060.3852image
ENSG00000096401.7,CDC5LTHCAGefitinibEAG3.3306e-06-0.2452image
ENSG00000096401.7,CDC5LTHYMAZD6244EAG2.5824e-03-0.4481image
ENSG00000096401.7,CDC5LUCECIPA.3EAG5.2594e-030.2643image
ENSG00000096401.7,CDC5LUCSAICAREAG2.9047e-020.3641image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType